Patents by Inventor Joseph P. Yevich

Joseph P. Yevich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-6-hydroxy-buspirone
    Patent number: 6821976
    Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: November 23, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • R-6-hydroxy-buspirone
    Patent number: 6686361
    Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: February 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Use of bioactive metabolites of gepirone for the treatment of psychological disorders
    Publication number: 20030220346
    Abstract: Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,dethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.
    Type: Application
    Filed: February 7, 2003
    Publication date: November 27, 2003
    Inventors: Stephen J. Kramer, Louis F Fabre, Edward H Ruediger, Joseph P Yevich
  • Antianxiety composition
    Publication number: 20030069251
    Abstract: An improved method of treating anxious patients involves direct administration of 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-dione (BMY 28674) or a pharmaceutically acceptable salt or hydrate formulated in appropriate pharmaceutical compositions to patients in need of such treatment. Syntheses of BMY 28674 are also provided.
    Type: Application
    Filed: July 23, 2002
    Publication date: April 10, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Edward H. Ruediger
  • R-6-hydroxy-buspirone
    Publication number: 20030055063
    Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.
    Type: Application
    Filed: July 22, 2002
    Publication date: March 20, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Methods for treating psychological disorders using bioactive metabolites of gepirone
    Patent number: 6534507
    Abstract: Bioactive gepirone metabolites, such as 3-OH gepirone (4,4,-dimethyl-3-hydroxy-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione), and their pharmaceutically acceptable salts and hydrates, can be used to alleviate psychological disorders or the symptoms thereof. The use of these compounds provides advantages over other therapeutic azapirones as they possess superior bioavailability, faster onset of action, and more stable plasma levels when administered to a mammal.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: March 18, 2003
    Assignee: Fabre-Kramer Pharmaceuticals, Inc.
    Inventors: Stephen J. Kramer, Louis F. Fabre, Edward H. Ruediger, Joseph P. Yevich
  • S-6-hydroxy-buspirone
    Publication number: 20030022899
    Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.
    Type: Application
    Filed: July 22, 2002
    Publication date: January 30, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Antipsychotic heterocycle compounds
    Patent number: 6476051
    Abstract: Compounds of Formula I: wherein Ar, Y, m, and Z are as defined in the specification, are useful antipsychotic and antidepressant agents demonstrating potent inhibition of 5-HT reuptake and dopamine D2 receptor antagonism.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: November 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Jun Yuan, Arlene S. Eison, Derek Denhart
  • Antipsychotic heterocycle compounds
    Publication number: 20020072611
    Abstract: Compounds of Formula I are useful antipsychotic and antidepressant agents demonstrating potent inhibition of 5-HT reuptake and dopamine D2 receptor antagonism.
    Type: Application
    Filed: December 12, 2000
    Publication date: June 13, 2002
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Jun Yuan, Arlene S. Eison, Derek Denhart
  • Antidepressant heterocyclic compounds
    Patent number: 6225324
    Abstract: Compounds of formula I are useful antidepressant agents demonstrating potent inhibition of 5-HT reuptake. Z is selected from among various phenyl and hetaryl moieties while Y is benzyl or indolyl.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 1, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ronald J. Mattson, Joseph P. Yevich
  • Quinazolinone inhibitors of cGMP phosphodiesterase
    Patent number: 6087368
    Abstract: Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: July 11, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Macor, David P. Rotella, Harold N. Weller, III, David W. Cushman, Joseph P. Yevich
  • Benzopyran derivatives as melatonergic agents
    Patent number: 6060506
    Abstract: Novel derivatives of benzopyran are provided which are useful as melatonergic agents.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: May 9, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Catt, Graham Johnson, Daniel J. Keavy, Ronald J. Mattson, Michael F. Parker, Katherine S. Takaki, Joseph P. Yevich
  • Benzodioxa alkylene ethers as melatonergic agents
    Patent number: 5981571
    Abstract: Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: November 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Catt, Graham Johnson, Daniel J. Keavy, Ronald J. Mattson, Michael F. Parker, Katherine S. Takaki, Joseph P. Yevich
  • Benzofuran and dihydrobenzofuran melatonergic agents
    Patent number: 5856529
    Abstract: Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: January 5, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Catt, Graham Johnson, Daniel J. Keavy, Ronald J. Mattson, Michael F. Parker, Katherine S. Takaki, Joseph P. Yevich
  • Biphenylamido derivatives as melatonergic agents
    Patent number: 5808151
    Abstract: There is provided novel biphenylamido derivatives of the formula ##STR1## wherein Z is ##STR2## and Y is H or Z is H and Y is ##STR3## n is 0 or 1; R is C.sub.1-6 alkyl;R.sup.1 is C.sub.1-3 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-4 alkoxymethyl, or NHR.sup.2 ; andR.sup.2 is C.sub.1-3 alkyl or cyclopropylwhich are melatonergic agents and are useful in the treatment of circadian rhythm-related disorders and other conditions affected by melatonin activity.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: September 15, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Epperson, Joseph P. Yevich
  • Antidepressant 1-arylalkyl-4-(alkoxy pyridinyl)-and 4-(alkoxypyrimidinyl) piperazine derivatives
    Patent number: 5763444
    Abstract: Novel compound of formula I and pharmaceutically acceptable salts thereof are useful CNS agents: ##STR1## wherein X is CH or N;X' is CH or a direct covalent link;Y is CH, CH.sub.2 or N;Y' is N, NH, O or S;R.sup.1 is H, Br, Cl, F, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, CN, CONH.sub.2 or CH.sub.3 SO.sub.2 NH;n is 2 or 3;R.sup.2 is H or C.sub.1-4 alkyl;R.sup.3 is C.sub.1-4 alkoxy;R.sup.4 is H, Br, Cl, or F; andZ is CH or N.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: June 9, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Joseph P. Yevich
  • Ethylamido fluorenes and improved method of making same
    Patent number: 5736578
    Abstract: Novel substituted fluorene compunds of Formula I are active as melatonergic agents: ##STR1## wherein: X=H, halogen, OH or OZ;Z=C.sub.1-6 alkyl; --(CH.sub.2).sub.m --CF.sub.3 (m=0-2); CD.sub.3 ; or ##STR2## n=1 or 2; and R=C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl, halogen substituted C.sub.1-6 alkyl, or C.sub.1-6 alkoxy substituted C.sub.1-6 alkyl.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: April 7, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brett T. Watson, Katherine S. Takaki, Joseph P. Yevich, James R. Epperson, George N. Karageorge, Karen L. Leboulluec
  • Ethylamino carbazole melatonergic agents
    Patent number: 5677328
    Abstract: Novel substituted carbazole compounds of Formula I are active as melatonergic agents: ##STR1## wherein: R.sub.1 is C(O)R.sub.3 or SO.sub.2 R.sub.4 ;R.sub.2 is H or C.sub.1-6 alkoxy;R.sub.3 is C.sub.1-6 alkyl, (CH.sub.2).sub.n SR.sub.4, (CH.sub.2).sub.n OR.sub.4, (CH.sub.2).sub.n SO.sub.2 R.sub.4, or NHR.sub.4 ;R.sub.4 is C.sub.1-4 alkyl; andm is 1 or 2; andn is 1 to 4.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: October 14, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Katherine S. Takaki, Marc A. Bruce, Graham S. Poindexter, Brett T. Watson, Joseph P. Yevich
  • Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
    Patent number: 5618816
    Abstract: A series of novel 5-(3,4-diamino-1,2,5-thiadiazole and S-oxide) derivatives of indolylalkylpiperazinyl pyridines and pyrimidines of Formula I are intended for use in the alleviation of vascular headaches. ##STR1## In Formula I, X is selected from S, SO and SO.sub.2.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: April 8, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronnie R. Crenshaw, Edward H. Ruediger, David W. Smith, Carola Solomon, Joseph P. Yevich
  • Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
    Patent number: 5521188
    Abstract: A series of novel 5-cyclobutenedione derivatives of indolylalkylpiperazinyl pyridines and pyrimidines of Formula I are intended for use in the alleviation of vascular headaches.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: May 28, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonas A. Gylys, Edward H. Ruediger, David W. Smith, Carola Solomon, Joseph P. Yevich, Pierre Dextraze